Adam Hakki (New York-Litigation), partner and Global Head of Shearman & Sterling’s Litigation Group, is a faculty member at the American Law Institute’s upcoming conference on Securities and Shareholder Litigation 2017: Cutting‐Edge Developments, Planning and Strategy, which was held on October 3, 2017 at Goodwin Procter’s New York office. The faculty at the conference included prominent securities litigators, government regulators and in-house litigation personnel at major financial institutions.

The conference provided an in-depth update on significant developments in federal and state securities and shareholder litigation and government enforcement. Hakki spoke on the following panel:

Developments in Securities Class Actions

• Confidential witness allegations: Treatment in ‘33 and ‘34 Act cases
• ‘33 and ‘34 Act liability for statements of opinion in the wake of Omnicare
• Class-wide measure of damages (BP), price impact (Halliburton and Petrobras), lags and market inefficiency – where do we go from here?
• Alleging statutory standing in ‘33 Act cases (ARIAD Pharmaceuticals, Century Aluminum, and MuniMae)
• ‘33 Act claims and statutes of repose (ANZ)
• SLUSA and ‘33 Act class actions in state court: Concurrent subject matter jurisdiction, removal, and self-help charter provisions (Cyan, FireEye, and the Snap IPO)
• Claims under Items 303 and 503 of Reg. S-K: Claims based on non-disclosure of trends, uncertainties, or risks under ’33 and ‘34 Acts (Leidos)